Expertise in
17
conditions

Dr. Nadine P. Santacruz

Hematology | Oncology
Brewer-Northern Light Cancer Care
33 Whiting Hill Rd, 
Brewer, ME 
Clinical Trials:Currently Recruiting for 7 Trials
Expertise in
17
conditions
Brewer-Northern Light Cancer Care
33 Whiting Hill Rd, 
Brewer, ME 

Overview

Nadine Santacruz is a Hematologist and an Oncologist practicing medicine in Brewer, Maine.

Dr. Santacruz is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Hepatoblastoma, Langerhans Cell Histiocytosis, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 52 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in NH

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

Brewer-Northern Light Cancer Care
33 Whiting Hill Rd, Brewer, ME 04412

Additional Areas of Focus

Dr. Santacruz has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

52 Clinical Trials

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Other
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Radiation, Drug, Procedure
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Topotecan, Vincristine
Study Phase: Phase 2
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Biological, Radiation, Other
Study Drugs: Carboplatin, Etoposide, Filgrastim, Ifosfamide, Mesna, Pegfilgrastim, Thiotepa
Study Phase: Phase 2
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Other
Study Phase: Phase 3
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
View 3 Less Clinical Trials

2 Total Publications

Early Lifestyle Intervention for Obesity Prevention in Pediatric Survivors of Acute Lymphoblastic Leukemia.
Early Lifestyle Intervention for Obesity Prevention in Pediatric Survivors of Acute Lymphoblastic Leukemia.
Journal: Nutrients
Published: September 26, 2019
Similar Doctors
Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Office

33 Whiting Hill Rd Ste 21, 
Brewer, ME 
 (1.0 miles away)
207-973-7478
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Audrey Garrett is an Oncologist practicing medicine in Brewer, Maine. Dr. Garrett is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Angiosarcoma, Inflammatory Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration.

Expertise in
58
conditions
Expertise in
58
conditions
Referral may be required

Brewer-Northern Light Cancer Care

33 Whiting Hill Rd, 
Brewer, ME 
 (0.1 miles away)
207-973-7478
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sheila Karina-Pascual is an Oncologist practicing medicine in Brewer, Maine. Dr. Karina-Pascual is highly rated in 58 conditions, according to our data. Her clinical expertise encompasses Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Familial Prostate Cancer, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration.

Expertise in
6
conditions
Dr. Robin E. Locke
Hematology | Oncology
Expertise in
6
conditions
Dr. Robin E. Locke
Hematology | Oncology
Referral may be required

Office

361 Old Belgrade Rd, 
Augusta, ME 
 (59.2 miles away)
207-621-6100
Languages Spoken:
English

Robin Locke is a Hematologist and an Oncologist practicing medicine in Augusta, Maine. Dr. Locke is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Pleuropulmonary Blastoma, Paget Disease of the Breast, Breast Cancer, and Endometrial Cancer.

Frequently Asked Questions about Dr. Nadine P. Santacruz

How do I make an appointment with Dr. Nadine P. Santacruz?

You can book an appointment with Dr. Nadine P. Santacruz by calling their office at 207-973-7478. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nadine P. Santacruz a top-rated expert for Hepatoblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nadine P. Santacruz is classified as an Advanced expert for Hepatoblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nadine P. Santacruz specialize in?

While Dr. Nadine P. Santacruz is a Hematology, they have specific expertise in Hepatoblastoma, Langerhans Cell Histiocytosis, and Histiocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Nadine P. Santacruz participate in research or clinical trials?

Yes. Dr. Nadine P. Santacruz has published 2 articles and abstracts on conditions like Hepatoblastoma. You can view a list of Dr. Nadine P. Santacruz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Nadine P. Santacruz accept my insurance?

Dr. Nadine P. Santacruz accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 207-973-7478 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Santacruz's expertise for a condition
ConditionClose
      View All 17 Advanced Conditions
      View All 48 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile